Combination therapy of ustekinumab and immunomodulator for inflammatory bowel disease: concerns about the different results observed between two meta-analyses

J Gastroenterol Hepatol. 2023 May;38(5):830-832. doi: 10.1111/jgh.16161. Epub 2023 Mar 12.

Authors

T Yoshihara¹, S Shinzaki^{1

2}, H Iijima¹, Y Tsujii¹, Y Hayashi¹, T Takehara¹

Affiliations

¹ Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan.
² Division of Gastroenterology and Hepatology, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Japan.

PMID: 36866596
DOI: 10.1111/jgh.16161

No abstract available

Publication types

Letter

MeSH terms

Combined Modality Therapy
Humans
Immunologic Factors
Inflammatory Bowel Diseases* / drug therapy
Treatment Outcome
Ustekinumab* / therapeutic use

Substances

Ustekinumab
Immunologic Factors